Shots:
- Kyowa Kirin to receive up front, regulatory & commercial milestones along with royalties and a share of sublicensing income. The company also has an option to retain rights in Japan
- Cerecor to get exclusive rights for the development, manufacturing and commercialization of CERC-00 for all indications globally including the US, EU and Japan
- The expanded agreement involves all indications of CERC-00 including severe pediatric onset inflammatory bowel disease and ARDS (including COVID-19 ARDS)
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Bio Tuesdays
The post Cerecor Signs a Worldwide License Agreement with Kyowa Kirin for CERC-00 first appeared on PharmaShots.
